Our data demonstrates that DDNDBeQ treatment leads to an increase in the number of ubiquitin-positive cells (Fig 5A and 5B, p<0.01) validating that VCP inhibition negatively impacts proteostasis, thereby potentially controlling NSCLC progression. Here, VCP is linked to non-small cell lung carcinoma.